Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Delivered strong Q4 performance across our value drivers Growth1 Q4 Group sales +6%; FY +4% Q4 IM sales +7%; FY +6% Q4 Sandoz sales +2%; FY -2% 1 Innovation LeqvioⓇ approved in US CosentyxⓇ Ph3 studies met primary endpoint in HS lanalumab positive Ph2 in Sjögren's T-Charge TM platform positive data in DLBCL and MM 3 Business development (ociperlimab, Gyroscope, ensovibep, UCB0599) Productivity1 Q4 Group core operating income +12%; FY +6% Q4 IM core operating income +15%; FY +10% Q4 IM core margin 33.6% (+2.4%pts cc); FY 36.2% 2 ESG 4 Improved scores for MSCI, ATMI AMR Benchmark, S&P Global Environmental targets on track (-34% Scope 1,2 GHG, -56% waste) Refreshed commitment statement on human rights IM Innovative Medicines division HS-Hidradenitis suppurativa DLBCL - Diffuse large B cell lymphoma MM Multiple myeloma 1. Q4 sales growth for Group, IM and Sandoz includes +1% point impact from a reclassification of contract manufacturing from other revenue to sales. Sandoz FY sales growth also benefited +1% point from this reclassification. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 49 of Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. 9 Investor Relations | Q4 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation